Bloomberg has a nice piece documenting a number of instances in which drug companies have promoted their drugs for uses not approved by the Food and Drug Administration and it harmed or killed patients. The part missing from this discussion is any discussion of the perverse incentives that patent monopolies create for promoting off-label uses. This is a strong argument for using alternative methods for financing research. By contrast, the article indicates that we have to hope that: "that drug companies actually honor the promises they keep making."
A second Trump administration will cement a right-wing majority on the Supreme Court for a generation, and put our collective future in the hands of someone who will be virtually unchecked by our institutions. The country has shifted rightward, and the reverberations will ensue for potentially the next few decades. In this climate, a robust independent media ecosystem will be more important than ever. We're committed to bringing you the latest news on how Trump's agenda will actually affect the American people, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in this country.
Quality journalism is expensive to produce, and we don't have corporate backers to rely on to fund what we do. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make our work possible. Any amount you give today will help us continue reporting on what matters to our democracy.
